Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bolt Biotherapeutics Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BOLT
Nasdaq
2836
https://boltbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bolt Biotherapeutics Inc
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Mar 21st, 2024 8:05 pm
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Feb 27th, 2024 12:00 pm
Pacira Appoints Frank D. Lee as Chief Executive Officer
- Dec 21st, 2023 12:30 pm
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
- Dec 5th, 2023 12:00 pm
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?
- Nov 20th, 2023 4:18 pm
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 9:05 pm
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
- Nov 7th, 2023 12:00 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- Oct 24th, 2023 4:30 pm
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
- Oct 23rd, 2023 2:30 pm
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
- Oct 18th, 2023 11:00 am
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
- Oct 17th, 2023 11:00 am
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
- Oct 16th, 2023 11:00 am
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
- Sep 28th, 2023 11:00 am
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
- Sep 12th, 2023 12:05 pm
Bolt Biotherapeutics to Participate in September Investor Conferences
- Sep 5th, 2023 8:15 pm
Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations
- Aug 9th, 2023 10:10 am
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 7th, 2023 8:10 pm
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
- Aug 3rd, 2023 11:30 am
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
- Jul 31st, 2023 9:27 pm
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
- Jun 13th, 2023 3:22 pm
Scroll